Modeling anti-myeloma activity of the anti-FcRH5/CD3 TDB in mice is challenging since anti-CD3 antibodies do not cross-react with mouse CD3 and there is no mouse FcRH5 ortholog. The gene discussed is FCRL5; the disease is plasma cell myeloma.